Cytotoxicity of monocrotaline in isolated rat hepatocytes: Effects of dithiothreitol and fructose

Laboratório de Bioquímica Metabólica e Toxicológica, UNESP-Univ Estadual Paulista, Campus de Dracena, 17900-000 Dracena, SP, Brazil.
Toxicon (Impact Factor: 2.49). 06/2011; 57(7-8):1057-64. DOI: 10.1016/j.toxicon.2011.04.010
Source: PubMed


Monocrotaline (MCT) is a pyrrolizidine alkaloid present in plants of the Crotalaria species that causes cytotoxicity and genotoxicity, including hepatotoxicity in animals and humans. It is metabolized by cytochrome P-450 in the liver to the alkylating agent dehydromonocrotaline (DHM). In previous studies using isolated rat liver mitochondria, we observed that DHM, but not MCT, inhibited the activity of respiratory chain complex I and stimulated the mitochondrial permeability transition with the consequent release of cytochrome c. In this study, we evaluated the effects of MCT and DHM on isolated rat hepatocytes. DHM, but not MCT, caused inhibition of the NADH-linked mitochondrial respiration. When hepatocytes of rats pre-treated with dexamethasone were incubated with MCT (5 mM), they showed ALT leakage, impaired ATP production and decreased levels of intracellular reduced glutathione and protein thiols. In addition, MCT caused cellular death by apoptosis. The addition of fructose or dithiotreitol to the isolated rat hepatocyte suspension containing MCT prevented the ATP depletion and/or glutathione or thiol oxidation and decreased the ALT leakage and apoptosis. These results suggest that the toxic effect of MCT on hepatocytes may be caused by metabolite-induced mitochondrial energetic impairment, together with a decrease of cellular glutathione and protein thiols.

Download full-text


Available from: Flávia Thomaz Verechia Pereira, Jul 28, 2014
  • Source
    • "However, this process is responsible for the toxic effects of numerous chemical compounds. The metabolites may cause adverse effects in the animal (Ioannides and Lewis, 2004; Mingatto et al., 2007; Maioli et al., 2011) by changing a fundamental cellular component (mitochondria, for example) at the cellular and molecular level, thus modulating its function (Meyer and Kulkarni, 2001). Due to the important functions of the liver in animals and previous studies that indicated the occurrence of liver damage after the use of ABA, this study aims to characterize the mechanisms of ABA toxicity on parameters related to bioenergetics and cell death and determine whether the toxicity induced by the compound is due to a possible activation following its metabolism in the liver. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abamectin (ABA), which belongs to the family of avermectins, is used as a parasiticide; however, ABA poisoning can impair liver function. In a previous study using isolated rat liver mitochondria, we observed that ABA inhibited the activity of adenine nucleotide translocator and F(o)F(1)-ATPase. The aim of this study was to characterize the mechanism of ABA toxicity in isolated rat hepatocytes and to evaluate whether this effect is dependent on its metabolism. The toxicity of ABA was assessed by monitoring oxygen consumption and mitochondrial membrane potential, intracellular ATP concentration, cell viability, intracellular Ca(2+) homeostasis, release of cytochrome c, caspase 3 activity and necrotic cell death. ABA reduces cellular respiration in cells energized with glutamate and malate or succinate. The hepatocytes that were previously incubated with proadifen, a cytochrome P450 inhibitor, are more sensitive to the compound as observed by a rapid decrease in the mitochondrial membrane potential accompanied by reductions in ATP concentration and cell viability and a disruption of intracellular Ca(2+) homeostasis followed by necrosis. Our results indicate that ABA biotransformation reduces its toxicity, and its toxic action is related to the inhibition of mitochondrial activity, which leads to decreased synthesis of ATP followed by cell death.
    Toxicology in Vitro 11/2012; 27(2). DOI:10.1016/j.tiv.2012.10.017 · 2.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malnutrition is very commonly seen in end stage liver disease. More than 65% of patients with chronic liver disease and more than 90% of patients with end-stage liver disease suffer malnutrition. Multiple reports have clearly shown that malnourishment is a relevant factor in complications and mortality due to chronic liver disease. It is essential that all patients with chronic liver disease have a full assessment of nutritional status at presentation. Supplementary enteral nutrition is indicated when chronic liver disease patients are unable to meet their nutritional requirements in their usual daily diet.
    01/2011; 31(4):228. DOI:10.7599/hmr.2011.31.4.228
  • [Show abstract] [Hide abstract]
    ABSTRACT: Severe forms of pulmonary arterial hypertension (PAH) are characterized by various degrees of remodeling of the pulmonary arterial vessels, which increases the pulmonary vascular resistance and right ventricular afterload, thus contributing to the development of right ventricle dysfunction and failure. Recent years have seen advances in the understanding of the pathobiology of PAH; however, many important questions remain unanswered. Elucidating the pathobiology of PAH continues to be critical to design new effective therapeutic strategies, and appropriate animal models of PAH are necessary to achieve the task. Although the monocrotaline rat model of PAH has contributed to a better understanding of vascular remodeling in pulmonary hypertension, we question the validity of this model as a preclinically relevant model of severe plexogenic PAH. Here we review pertinent publications that either have been forgotten or ignored, and we reexamine the monocrotaline model in the context of human forms of PAH.
    AJP Lung Cellular and Molecular Physiology 09/2011; 302(4):L363-9. DOI:10.1152/ajplung.00212.2011 · 4.08 Impact Factor
Show more